These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 12533270)

  • 41. Examining the effects of adjuvant chemotherapy on cognition and the impact of any cognitive impairment on quality of life in colorectal cancer patients: study protocol.
    Dwek MR; Rixon L; Simon A; Hurt C; Newman S
    BMC Psychol; 2015 Nov; 3():43. PubMed ID: 26612628
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neurotoxic Effects of Anthracycline- vs Nonanthracycline-Based Chemotherapy on Cognition in Breast Cancer Survivors.
    Kesler SR; Blayney DW
    JAMA Oncol; 2016 Feb; 2(2):185-92. PubMed ID: 26633037
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cognitive problems after chemotherapy for breast cancer.
    Harv Womens Health Watch; 2002 Oct; 10(2):5-6. PubMed ID: 12393318
    [No Abstract]   [Full Text] [Related]  

  • 44. Adjuvant chemotherapy for breast cancer and cognitive impairment.
    Marín AP; Sánchez AR; Arranz EE; Auñón PZ; Barón MG
    South Med J; 2009 Sep; 102(9):929-34. PubMed ID: 19668023
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer.
    Stewart A; Bielajew C; Collins B; Parkinson M; Tomiak E
    Clin Neuropsychol; 2006 Feb; 20(1):76-89. PubMed ID: 16410227
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cognitive effects of chemotherapy in breast cancer patients: a dose-response study.
    Collins B; MacKenzie J; Tasca GA; Scherling C; Smith A
    Psychooncology; 2013 Jul; 22(7):1517-27. PubMed ID: 22936651
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study.
    Hermelink K; Untch M; Lux MP; Kreienberg R; Beck T; Bauerfeind I; Münzel K
    Cancer; 2007 May; 109(9):1905-13. PubMed ID: 17351951
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A prospective surveillance model for physical rehabilitation of women with breast cancer: chemotherapy-induced peripheral neuropathy.
    Stubblefield MD; McNeely ML; Alfano CM; Mayer DK
    Cancer; 2012 Apr; 118(8 Suppl):2250-60. PubMed ID: 22488699
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cognitive dysfunction following adjuvant treatment of breast cancer: a new dose-limiting toxic effect?
    Ganz PA
    J Natl Cancer Inst; 1998 Feb; 90(3):182-3. PubMed ID: 9462670
    [No Abstract]   [Full Text] [Related]  

  • 50. Cognitive dysfunction following adjuvant chemotherapy for breast cancer: two case studies.
    Paraska K; Bender CM
    Oncol Nurs Forum; 2003; 30(3):473-8. PubMed ID: 12719746
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Objective and self-reported cognitive dysfunction in breast cancer women treated with chemotherapy: a prospective study.
    Biglia N; Bounous VE; Malabaila A; Palmisano D; Torta DM; D'Alonzo M; Sismondi P; Torta R
    Eur J Cancer Care (Engl); 2012 Jul; 21(4):485-92. PubMed ID: 22211832
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment.
    Collins B; Mackenzie J; Stewart A; Bielajew C; Verma S
    Psychooncology; 2009 Feb; 18(2):134-43. PubMed ID: 18551510
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mild cognitive impairment after adjuvant chemotherapy in breast cancer patients--evaluation of appropriate research design and methodology to measure symptoms.
    Matsuda T; Takayama T; Tashiro M; Nakamura Y; Ohashi Y; Shimozuma K
    Breast Cancer; 2005; 12(4):279-87. PubMed ID: 16286908
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy.
    Ferguson RJ; McDonald BC; Saykin AJ; Ahles TA
    J Clin Oncol; 2007 Sep; 25(25):3866-70. PubMed ID: 17761972
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Systemic (adjuvant) treatment of primary breast cancer.
    Somani N
    J Assoc Physicians India; 2001 Apr; 49():451-3. PubMed ID: 11762618
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Brain vulnerability to chemotherapy toxicities.
    Ahles TA
    Psychooncology; 2012 Nov; 21(11):1141-8. PubMed ID: 23023994
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neuropsychological functioning and quality of life during the first year after completing chemotherapy for breast cancer.
    Reid-Arndt SA; Hsieh C; Perry MC
    Psychooncology; 2010 May; 19(5):535-44. PubMed ID: 19472296
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Prevalence and course of fatigue in breast cancer: the kind of chemotherapy plays a role].
    de Jong N; Candel M; Schouten H; Abu-Saad HH; Courtens A
    Pflege Z; 2005 Feb; 58(2):100-3. PubMed ID: 15754508
    [No Abstract]   [Full Text] [Related]  

  • 59. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy.
    Koppelmans V; Breteler MM; Boogerd W; Seynaeve C; Gundy C; Schagen SB
    J Clin Oncol; 2012 Apr; 30(10):1080-6. PubMed ID: 22370315
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The post-treatment cognitive impairment ("chemobrain") in breast cancer patients. Short review.].
    Nagykálnai T; Landherr L
    Magy Onkol; 2017 Dec; 61(4):349-351. PubMed ID: 29257154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.